# The Enzyme Behind Cannabis and Endocannabinoid Regulation > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/the-enzyme-behind-cannabis-and-endocannabinoid-regulation/ > **Published:** 2026-08-15T07:10:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:12:12-04:00 > **Clinical Summary:** FAAH inhibitors enhance anandamide signaling. Learn how FAAH enzyme regulation differs from cannabis and impacts clinical response. --- ✦ New CED Clinical Relevance #82 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchNeurology[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)AnxietyPainSafetyAging Why This Matters Clinicians should understand FAAH’s role in regulating endogenous cannabinoids because genetic variations in this enzyme affect how patients metabolize both natural endocannabinoids and exogenous cannabis, potentially explaining variable treatment responses and adverse effects. Patients with FAAH polymorphisms may require personalized dosing strategies, and FAAH inhibitors represent an emerging therapeutic class that could treat pain and neuropsychiatric conditions without the psychoactive effects of direct [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). This knowledge enables clinicians to better counsel patients on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and anticipate individual differences in efficacy and tolerability. Clinical Summary FAAH (fatty acid amide hydrolase) is a key enzyme that breaks down anandamide, an endogenous cannabinoid naturally produced in the human body, and its regulation directly influences [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) signaling and downstream physiological effects. Variations in FAAH expression and activity affect how efficiently the body metabolizes endocannabinoids, which has implications for pain perception, mood regulation, appetite, and immune function. Genetic polymorphisms in the FAAH gene can influence individual susceptibility to various conditions and may affect how patients respond to both exogenous cannabis and endocannabinoid-targeted therapies. Understanding FAAH’s role provides mechanistic insight into why different patients may experience variable clinical responses to cannabis, potentially explaining differences in therapeutic efficacy and side effect profiles across the patient population. Clinicians should consider that patients with naturally lower FAAH activity may accumulate higher anandamide levels and potentially experience different cannabis effects or may benefit from lower dosing strategies tailored to their endocannabinoid metabolism. Dr. Caplan’s Take “FAAH’s role in breaking down anandamide is biologically plausible and has generated interesting mechanistic hypotheses, but we’re still largely in the preclinical and early human phase with this work, so I’m cautious about drawing clinical conclusions until we see robust randomized controlled trials demonstrating meaningful [patient outcomes](https://cedclinic.com/uk-medical-cannabis-chronic-pain-outcomes-patient-insights/).” Clinical Perspective 💊 Understanding FAAH’s role in endocannabinoid metabolism provides important context for how cannabis affects the human body, since FAAH enzymatically degrades anandamide, a key endogenous cannabinoid involved in pain regulation, mood, and appetite control. FAAH inhibition, whether through [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) or genetic variation, can increase anandamide levels and theoretically enhance these physiological effects, though the clinical significance of this pathway in individual patients remains incompletely characterized. Important confounders include genetic polymorphisms in FAAH that create variable individual responses to cannabinoids, concurrent medications that may interact with this enzyme system, and the fact that exogenous cannabis delivers THC and CBD through entirely different mechanisms than endogenous anandamide regulation. Clinicians should recognize that elevated endocannabinoid tone from FAAH inhibition does not necessarily predict therapeutic benefit or adverse effects in a given 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20Enzyme%20Behind%20Cannabis%20and%20Endocannabinoid%20Regulation%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73451)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73451)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20Enzyme%20Behind%20Cannabis%20and%20Endocannabinoid%20Regulation%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73451)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Histamine Brain Mapping Study 2026: ADHD, Depression, Schizophrenia](https://cedclinic.com/histamine-brain-mapping-psychiatric-disorders/) - [CBD and Liver Enzymes: What the New JAMA Study Actually Shows](https://cedclinic.com/cbd-liver-enzyme-elevation-study-jama-2025/) - [7 Surprising Long-Term Effects of Cannabis That Actually Help You Heal](https://cedclinic.com/long-term-effects-of-cannabis-healing/) 📰 Source: [https://cannabisshop.com/the-enzyme-behind-cannabis-and-endocannabinoid-regulation/](https://cannabisshop.com/the-enzyme-behind-cannabis-and-endocannabinoid-regulation/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).